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Background: Natural Killer (NK) cells are a crucial component of the host innate immune system with anti-viral
and anti-cancer properties. However, the role of NK cells in West Nile virus (WNV) infection is controversial, with
reported effects ranging from active suppression of virus to no effect at all. It was previously shown that K562-
mb15-41BBL (K562D2) cells, which express IL-15 and 4-1BBL on the K562 cell surface, were able to expand and
activate human primary NK cells of normal peripheral blood mononuclear cells (PBMC). The expanded NK cells
were tested for their ability to inhibit WNV infection in vitro.
Results: Co-culture of PBMC with irradiated K562D2 cells expanded the NK cell number by 2-3 logs in 2-3 weeks,
with more than 90% purity; upregulated NK cell surface activation receptors; downregulated inhibitory receptors;
and boosted interferon gamma (IFN-g) production by ~33 fold. The expanded NK (D2NK) cell has strong natural
killing activity against both K562 and Vero cells, and killed the WNV infected Vero cells through antibody-
dependent cellular cytotoxicity (ADCC). The D2NK cell culture supernatants inhibited both WNV replication and
WNV induced cytopathic effect (CPE) in Vero cells when added before or after infection. Anti-IFN-g neutralizing
antibody blocked the NK supernatant-mediated anti-WNV effect, demonstrating a noncytolytic activity mediated
through IFN-g.
Conclusions: Co-culture of PBMC with K562D2 stimulatory cells is an efficient technique to prepare large
quantities of pure and active NK cells, and these expanded NK cells inhibited WNV infection of Vero cells through
both cytolytic and noncytolytic activities, which may imply a potential role of NK cells in combating WNV infection.
Background
Natural killer (NK) cells are able to kill viral infected
cells directly and produce inflammatory cytokines that
limit infection. NK cell activation is controlled by the
integration of signals from activation and inhibitory
receptors. The NK cells from normal blood donors are
usually in inhibitory states, but can be activated, either
directly or indirectly, through CD4
+ T cells, dendritic
cells (DC), monocytes/macrophages, or NKT cells. Inter-
ferons, and macrophage-derived cytokines, including IL-
1b, IL-2, IL-12, IL-15, IL-18, and TNF-a can contribute
to NK cell activation directly in a MHC class I indepen-
dent manner [1].
NK cells should have anti-WNV properties. However,
surprisingly few experiments have been published
describing the antiviral activity of NK cells against
WNV or other flaviviruses [2]. Knowledge about NK
cells in WNV infection is limited to the analysis of NK
cell activity during WNV infections in humans and NK
cell depleted mice. Infection of mice with WNV transi-
ently activates and then suppresses NK cell activity [3].
WNV infection may attenuate NK cell cytotoxicity by
increasing cell surface expression of MHC class I mole-
cules [4-6] to overcome susceptibility to NK cell
mediated lysis. Splenocytes from WNV immunized mice
have poor NK cell lytic activity [7]. Mice genetically
deficient in NK cells or with NK cells depleted by anti-
NK cell antibody demonstrate no increased morbidity or
mortality for WNV infection when compared to wild
type controls [2,8]. Thus, at least for WNV infection in
mice, NK cells appear to be dispensable for controlling
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any medium, provided the original work is properly cited.infection and disease, despite their well documented role
in combating viral infection in general.
Presumably NK cell knockout or NK cell depletion
does not promote WNV infection of mice because NK
cell functions are effectively inhibited by WNV. NK cells
may be able to control WNV infection if this inhibition
is alleviated or bypassed. Encouraged by recent advance-
ments in cancer treatment with NK cells [9-11],
expanded, activated NK cells from human peripheral
blood mononuclear cells (PBMC) in vitro were prepared,
and tested for the ability to inhibit WNV in tissue cul-
ture. The in vitro expanded NK cells were demonstrated
to inhibit WNV infection of Vero cells efficiently. This
underscores the potential importance of NK cells in
controlling WNV infection.
Results
Co-culture with radiation killed stimulating cells in vitro
significantly expanded NK cells in human PBMC
In co-cultures with 1 × 10
7 lethally radiated K562-
mb15-41BBL (K562D2) stimulating cells in vitro,1×1 0
7
PBMC were expanded to 1 × 10
8 in 2 weeks. CD56
+ (a NK
cell marker) and CD3
+ (a T cell marker) cells changed
from 9.60% and 53.22% before expansion to 91.20% and
6.60% respectively after expansion (Figure 1). The absolute
CD56
+ cell number increased from about 1 million to 100
million, or about 100 fold. The absolute CD3
+ cell number
remained the same, but the CD3
+/CD56
+ ratio changed
from about 5.5 before expansion to about 0.07 after expan-
sion, or a decrease of about 2 logs. Since culture medium
alone has been well documented to give only about a 2- to
5-fold expansion of CD56
+CD3
- NK cells [12], a control
for this was not included in this experiment. K562D2
stimulatory cells disintegrate and disappear over about 7
days in the culture. The results in this paper represent
more the 40 expansions with fresh or frozen PBMC.
Expanded NK cells are cytolytic through both natural
killing and ADCC
D2NK cells expanded by co-culture with K562D2 stimu-
latory cells have been reported to have enhanced cytolytic
function against B-lineage cell lines [12]. In this study,
K562 and Vero cells were used as target cells because
K562 is a standard target cell for NK cell cytotoxicity
assay and Vero cells were used for WNV infection and
anti-WNV assays in our protocols. In a 4-hour cytotoxi-
city assay, D2NK cells expanded with K562D2 showed
very strong cytotoxicity, compared to NK92 and NKL
cell lines [12], against uninfected K562 target cells at
effector:target ratios ranging from 10:1 to 1:1 (Figure 2a).
As shown in Figure 2b, D2NK cells were cytotoxic to
both normal Vero cells and WNV infected Vero cells,
and WNV infection made the Vero cells more susceptible
to D2NK killing. Antibody from WNV-hyperimmune
ascetic fluid enhanced D2NK cytotoxicity to WNV
infected Vero cells by greater than two-fold at the 10:1 E:
T ratio tested. Control ascetic fluid containing unrelated
antibody (HIV-1 RT specific McAb) had no effect on kill-
ing (Figure 2b, “Ab Control), excluding the possibility of
nonspecific killing by IgG or other components of ascetic
fluid in the ADCC assay. This result represents 6 cyto-
toxicity assays performed.
Expanded NK cells are activated
NK cell related surface receptors other than CD56 and
CD3 were also assessed by FACS. NKG2D, NKp30,
NKp44, and NKp46 are NK cell activation receptors;
CD158a, CD158b, NKB1, and NKAT2 are NK cell
Figure 1 In vitro expansion of PBMC enriched CD56+ cells. NK cells before and 2 weeks after expansion by co-culture with K562-mb15-
41BBL (D2NK) cells were stained with anti-CD56-PE and anti-CD3-FITC antibodies as the markers for NK cells and T cells, and then analyzed by
flow cytometry. The UL quadrant counts (NK cells) are 9.60% and 91.20% for PBMC-Day 0, D2NK-Day 14 respectively; The LR quadrant counts (T
cells) are 53.22% and 6.60% for PBMC-Day 0, D2NK-Day 14 respectively. PBMC isolated from the Buffy coat were either cultured freshly, or after
frozen storage in liquid nitrogen, with equivalent results. The data presented in this figure is typical of 12 expansions made from the PBMC of 5
different donors. Averaged over these 12 experiments, NK cells were 10.05% ± 4.42 and T cells 52.44% ± 6.71 CD3+ before expansion. After
expansion, NK cells were 85.25% ± 12.53 and T cells 12.12% ± 5.52 CD3+.
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Page 2 of 9inhibitory receptors [13-15]. The results from 2 donors
are shown in Figure 3. The expression rates of the acti-
vation receptors (Figure 3a) on the NK cells expanded
using K562D2 are much higher than on the PBMC
before expansion. For example, NKG2D
+/CD56
+ cells
increased from 30% in PBMC to more than 95% in
D2NK. However, D2NK cells had little influence on
expression of inhibitory receptors (Figure 3b), with the
exception of a reduction of CD158b. CD94
+/CD56
+,a n
activating or inhibitory KIR (depending upon which
downstream receptor it activates) increased from 48% in
PBMC to 86% in D2NK (Figure 3a).
Significant changes in the expression of cytolytic
receptors during a number of co-culture experiments
were observed. The inhibitory CD158b
+/CD56
+cells


























































Figure 2 Cytotoxicity of the D2NK cells. (a) Natural killing activities of NK92, NKL cell lines and in vitro expanded primary D2NK cells. The
effector cells were NK92, NKL, D2NK cells, the target cells were K562 cells; the effector: target ratio were 10:1, and 1:1; reaction at 37°C for 4
hours. (b) Natural killing and ADCC of D2NK cells against normal and WNV infected Vero cells. The ADCC group was done with effector cell,
target cells, and WNV specific hyper-immune ascetic fluid; the natural killing group was done with effector cells, target cells, but no antibody; the
Ab control group was done with effector cell, target cells, and HIV-1 RT specific ascetic fluid as nonspecific antibody and ascetic fluid control; the
target cells were Vero cells either uninfected or 48 hours post infection with 100 TCID50 units of WNV; the effector cells were in vitro expanded
D2NK cells; the E:T ratio was 10:1; WNV hyper-immune acetic fluid and HIV-1 RT McAb in acetic fluid were used at 1:1000 dilutions for ADCC; All
reactions were performed in triplicate. The SD is the standard deviation from 6 tests with NK cells expanded from 6 different donor PBMC.
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Page 3 of 9(Figure 3b); whereas the activating NKp30
+/CD56
+cells
increased from 24% in PBMC to 64% in D2NK, and the
activating NKp46
+/CD56
+cells increased from 58% in
PBMC to 73% in D2NK (Figure 3a). The most signifi-
cant change was the activating NKp44
+/CD56
+ expres-
sion, from an almost undetectable 0.31% in PBMC to
65% in D2NK after expansion. This corresponded to a
more than 208 fold increase (Figure 3a).
Because upregulated IFN-g production is another
important characteristic of activated NK cells, The IFN-
g levels in PBMC and D2NK cell culture supernatants
were measured. In 2 ml cultures containing 2 × 10
6
cells each, D2NK cells produced 4871 pg/ml vs. 154 pg/
ml IFN-g produced by PBMC in 48 hours, or about 33









CD94 NKG2D NKp46 NKp30 NKp44




























CD158b CD158a NKB1 NKAT2




















Figure 3 Effects of in vitro expansion on expression of NK cell receptors. D2NK cells were stained with PE or FITC conjugated antibodies
against (a) cell activating receptors, NKG2D, NKp30, NKp44, NKp46 NK, or (b) cell inhibitory receptors, CD158a, CD158b, NKB1, NKAT2 NK, and
then analyzed by flow cytometry. CD94 can be either an activation or inhibitory KIR, according to which downstream receptor it activates. The
data presented represent the combined results from two donors, one tested in singlicate, another tested in duplicate. The error bars represent
standard deviations, according equal weight to all three assays.
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replication in Vero cells
As shown in table 1, D2NK cells at 10 million/T25 flask,
and NK cell culture supernatants at a 1:2 dilution com-
pletely inhibited WNV induced CPE in Vero cells until
day 10 post-infection when cultures were terminated. NK
cells at 1 million/T25 flask, and NK cell culture superna-
tants at 1:10 dilution significantly delayed the WNV
induced CPE in Vero cells. In control experiments,
neither NK cells nor NK cell culture supernatants at the
concentrations tested induced CPE in Vero cells (data
not shown). The inhibitory effects of NK cells and NK
cell culture supernatants on WNV replication in Vero
cells were further confirmed with TaqMan RT-PCR of
viral RNA extracted from the culture supernatants col-
lected on day 10 post infection (Figure 5). The NK cells
reduced WNV viral load in a cell number dependent
manner, and supernatants reduced the WNV viral load
in a dose dependent manner.
Anti-IFN-g antibody neutralized NK cell supernatant
inhibition of WNV replication in Vero cells
When anti-IFN antibodies were individually pre-incu-
bated with D2NK cell culture supernatant, only anti-
IFN-g inhibited the ability of NK cell supernatants to
suppress WNV infection of Vero cells (Table 2). In con-
trol experiments, supernatant from the irradiated
K562D2 cells alone had no inhibitory effect on WNV
infection of Vero cells (Table 2, Figure 6).
Pretreatment with NK cell supernatants made Vero cells
resistant to WNV infection
Pretreatment of Vero cells with D2NK cell supernatant



























Figure 4 IFN-g production of the expanded NK cells. Supernatants from 6 × 10
6 PBMC, D2NK cells cultured for 48 hours at a 6-well plate in 2
ml medium were tested with human IFN-g EIA kit. The concentrations of IFN-g from PBMC and D2NK are 154 ± 12 pg/ml, and 5052 ± 493 pg/
ml respectively; the culture medium has no detectable human IFN-g. The PBMC and D2NK from 3 different donors were tested in triplicate for
each. The error bars represent SD.
Table 1 D2NK cells and D2NK cell culture supernatants inhibited WNV induced CPE in Vero cells.
Days Post Treatment 1 2 3 4 5 7 8 9 10
Normal control - - - - - - - - -
WNV control - - + + 3+ 4+ 4+ 4+ 4+
NK cells 10 million - - - - - - - - -
NK cells 1 million - - - - + 4+ 4+ 4+ 4+
NK cells 0.1 million - - - + 2+ 4+ 4+ 4+ 4+
NK sup 1:2 - - - - - - - - -
NK sup 1:10 - - - - + 4+ 4+ 4+ 4+
NK sup 1:100 - - - + 2+ 4+ 4+ 4+ 4+
NK sup1:1000 - - - + 3+ 4+ 4+ 4+ 4+
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~4 logs as measured by TaqMan RT-PCR on day 10
post infection. By comparison, pretreatment with con-
trol supernatants had no inhibitory effect on WNV
RNA copy numbers (Figure 7).
Discussion
NK cells are activated during a wide variety of viral
infections by virus-induced type I IFNs. The importance
of the NK cell defense against virus infections is high-
lighted by the susceptibility of mice depleted of NK cells
to many experimental infections and by the invasive or
disseminated viral disease that is associated with natu-
rally occurring NK cell deficiencies in humans [16].
However, many viruses, including WNV, have developed
mechanisms to evade the NK cell response. These
mechanisms include expression of MHC class I
homologs encoded by viruses, selective modulation of
MHC class I protein expression, inhibition of activating
receptor function and production of cytokine-binding
proteins or cytokine-receptor antagonists encoded by
viruses [17]. These mechanisms also include direct viral
e f f e c t so nN Kc e l l s ,s u c ha si n f e c t i o no fN Kc e l l sa n d
viral envelope protein blockage of non-class I NK cell
inhibitory receptors [2-4,6,17]. Mice genetically deficient
in NK cells or depleted of NK cells by anti-NK cell anti-
body demonstrated no increased morbidity or mortality
compared to controls when infected with WNV [2,8].
However, it would seem that this apparent lack of NK
protection is only because WNV normally suppresses or
bypasses the NK response. Therefore, it is reasonable to
expect that blocking the viral evasion process and rein-
forcing NK cell function might lead to improved control














































Figure 5 NK cells and supernatants inhibited WNV replication in Vero cells. NK cells or culture supernatants were added to WNV-infected
or control Vero cultures 2 hours post infection. Supernatants from testing and control Vero cell cultures were collected on day 10 post WNV
infection, and WNV RNA was extracted with Qiagen viral extraction kit and then analyzed with TaqMan RT-PCR. The NK cell culture supernatant
was from D2NK cells.
Table 2 Anti-IFN-g antibody blocks D2NK supernatant inhibition of WNV CPE in Vero cells.
Days Post Treatments 1 2 3 567891 2 1 3
Normal control - - - -------
WNV control - - - 2+ 4+ 4+ 4+ 4+ 4+ 4+
Control Sup 1:2 - - - 2+ 3+ 4+ 4+ 4+ 4+ 4+
N K S u p 1 : 2 - - - -------
NK Sup 1:2 + a IFN-a
a - - - -------
NK Sup 1:2 + a IFN-b
a - - - -------
NK Sup 1:2 + a IFN-g
a - - - 1 +2 +3 +3 +4 +4 +4 +
The diluted D2NK cell culture supernatant was incubated with anti-IFN-a, anti-IFN-b, or anti-IFN-g antibody at 37°C for 1 hour before being applied to the WNV
infected Vero cells.
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NK cells over a hundred fold, but also activated NK cells.
All of the activating receptors tested including NKG2D,
NKp30, NKp44, and NKp46 were upregulated after
expansion. Most noticeably, NK cells expressing the nat-
ural cytotoxicity receptor, NKp44, were up regulated
from only 0.31% before to 64.59% after expanding, which
corresponds to a greater than 200-fold increase.
Consistent with the upregulated natural killing receptors,
the D2NK cells are more potent in killing K562 target
cells (Figure 2a) than either the NK92 or NKL cell lines.
The inhibitory markers in D2NK cells showed very small
changes, although CD158b appeared to be modestly
downregulated. Further studies would be required to
determine whether the small CD158a downregulation is
statistically significant. The upregulation of the activation
Figure 6 Anti-IFN-g antibody neutralized NK cell supernatant inhibition of WNV replication in Vero cells. NK culture supernatants with
and without antibodies to IFNs were added to WNV-infected or control Vero cultures 2 hours post infection. Supernatants from testing and
control Vero cell cultures were collected 10 days post WNV infection, and WNV RNA was extracted with Qiagen viral extraction kit and then






























Figure 7 NK cell supernatant pretreatment made Vero cells resistant to WNV infection. Vero cell cultures were treated with NK cell culture
supernatants or control supernatants overnight prior to infection with WNV. Supernatants from testing and control Vero cell cultures were
collected 10 days post WNV infection, and WNV RNA was extracted with Qiagen viral extraction kit and then analyzed with TaqMan RT-PCR. The
NK cell culture supernatant was from D2NK cells.
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one of the inhibitory receptors suggest an overall bias
towards an activation profile in D2NK cells. The upregu-
lation of the IFN-g production of D2NK cells (Figure 4)
with no detectable IL-10 (data not shown) both before
and after expansion further confirmed the activation sta-
tus of the D2NK cells. We have tried to measure TGF-b
production by D2NK, but have so far been unable to
detect TGF-b above the high background concentration
of TGF-b in the culture medium. We have not yet
attempted to expand NK cells in serum-free medium.
The NK cell lines, NK92 and NKL, have efficacy dis-
advantages compared to D2NK. Both cell lines have less
natural killing activity than D2NK (Figure 2a). NK92 has
no ADCC activity because it lacks FcR and NKL has
only weak ADCC in our assays (not shown). D2NK
shows strong ADCC (Figure 2b). ADCC activity has
been shown to play an important role in anti-cancer
therapy and in the light of data presented here may war-
rant assessment for function in combating WNV infec-
tion. The WNV infected Vero cells are more susceptible
to D2NK killings than normal Vero cells by both ADCC
and natural killing. It should be interesting to further
study the underneath mechanisms.
The inhibition of WNV replication by NK cells deliv-
ered prior or post infection observed in this study, sug-
gests the possibility of controlling WNV infection by
adoptive transfer of NK cells expanded in vitro. It
remains to be determined whether the direct cytotoxi-
city and ADCC or the endogenous production of IFN-g
afforded by these expanded NK cells provides advan-
tages over alternative treatments for WNV such as
direct administration of IFN-g.
Conclusions
Co-culture of human PBMC with irradiated K562D2 sti-
mulatory cells together with medium supplemented with
IL-2 efficiently expanded and activated NK cells, as mea-
sured by IFN-g production, direct cytotoxicity, ADCC
and surface expression of NK activation markers. The in
vitro expanded D2NK cells and their culture supernatant
inhibited WNV infection of Vero cells. These results
help characterize the potential role of NK cells in WNV
infection and demonstrate that NK cells are capable of
combating WNV infections in the right conditions.
Methods
K562D2 Stimulatory cells
The co-stimulatory cell line, K562-mb15-41BBL
(K562D2), expressing IL-15 and 4-1BB ligand on K562 cell
surface [12], was kindly provided by Dr. Dario Campana.
NK cells and NK cell culture supernatants preparation
Human PBMC were isolated from Buffy coats (from the
NIH blood bank) by Histopaque (Sigma, St. Louis, MO),
then incubated with equal numbers of lethally irradiated
(10,000 rads) stimulating cells in the presence of 10 IU/
ml human IL-2 (National Cancer Institute BRB Preclini-
cal Repository, Rockville, MD) in RPMI 1640 and 10%
FCS according to Imai C et al. [12]. The co-culture
lasted for 2-3 weeks, with a 50% media change every 2
days after the first week. D2NK (NK cells expanded
with K562D2 stimulatory cells) and their supernatants
were collected 48 h after the last media change by cen-
trifugation; NK cells were washed once with PBS before
analysis, or application to WNV infected Vero cells for
anti-WNV assays.
The PBMC before expansion and the expanded D2NK
cells were all independently analyzed by FACS for surface
receptors after staining with antibody conjugates includ-
ing hCD3-FITC, hCD16-FITC, hCD56-PE, hCD158a-PE,
hCD185b-FITC, hCD94-FITC, hCD158e1 (NKB1)-FITC,
hCD158b1/b2 (KIR-NKAT2)-PE (BD Biosciences, San
Diego, CA); and NKG2D-PE, NKp30-PE, NKp46-PE,
NKp44-PE (Coulter, Fullerton, CA).
Supernatants from co-cultivated NK and from the
control (stimulatory cells alone, without PBMC) were
independently filtered through 0.2 um filters, and either
used immediately or stored at -70°C in aliquots. In
order to measure the IFN-g concentration with EIA kit
(R&D Systems, Minneapolis, MN) in the supernatants,
6×1 0
6 PBMC, D2NK cells were replated into a single
well of 6-well plate in 2 ml of the NK cells culture med-
ium, and cultured for 48 h at 37°C before harvest.
Cytotoxicity assays
The CytoTox 96® Non-Radioactive Cytotoxicity Assay
k i tf r o mP r o m e g a( M a d i s o n ,W I )w a su s e dt om e a s u r e
the direct cytotoxicity of the NK cells. K562 cells, nor-
mal Vero cells and Vero cells 48 hours after 100
TCID50 of WNV strain FDA/HU-02 (GB# AY646354)
infection were used as the target cells. Target cells at
2.5 × 10
4 were dispensed into 96-well U-bottom plates
(Becton Dickinson, San Jose, CA) in triplicate. Effector:
target cells ratios of 10:1 and 1:1 were mixed in a final
volume of 200 μl per well and incubated for 4 hours at
37°C in a 5% CO2 incubator. Anti-WNV antibody of
WNV hyperimmune ascetic fluid from ATCC (Rockville,
MD) was used at 1:1000 dilutions for ADCC assay, anti-
HIV-1 RT McAb in ascetic fluid (catalog # 2483) from
NIH AIDS Research & Reference Reagent Program
(Gaithersburg, MD) was used as the negative control.
The following formula was used to calculate the percent
cytotoxicity: % Cytotoxicity = (Experimental - Effector
Spontaneous - Target Spontaneous) 100/(Target Maxi-
mum - Target Spontaneous).
WNV infection of Vero cells
1×1 0
6 Vero cells were cultured in T25 flasks, infected
w i t h1 0 0T C I D 5 0o fW N Vs t r a i nF D A / H U - 0 2( G B #
AY646354)[16] at 37°C for 2 h, then cultured at 37°C in a
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supernatants were collected at indicated time points for
WNV viral RNA extraction and TaqMan RT-PCR [17].
NK cell and NK cell culture supernatant treatment of WNV
infected Vero cells
D2NK cells at different concentrations and D2NK cell
culture supernatants at different dilutions were added to
the WNV infected Vero cells in T25 flasks in duplicate
and observed daily for CPE. Culture supernatants were
collected for WNV viral RNA extraction and TaqMan
RT-PCR [17] analysis at day 7. The control supernatants
were collected from lethally irradiated stimulatory cell
alone cultures without PBMC.
NK cell culture supernatant treatment with anti-IFN
antibodies
IFN-a,I F N - b,I F N - g (NIAID Reference Reagent Reposi-
tory, Gaithersburg, MD) were tested in WNV infection of
Vero cells, and confirmed all 3 IFNs were able to inhibit
WNV replication; anti-IFN-a antibody, anti-IFN-b anti-
body, and anti-IFN-g antibody (NIAID Reference Reagent
Repository, Gaithersburg, MD) were tested and con-
firmed of their neutralization activities against corre-
sponding IFN. D2NK cell culture supernatants were
diluted 1:2 with culture medium, and supplemented with
anti-IFN antibodies individually at a dilution of 1:1000,
incubated at 37°C for 1 h before addition to Vero cells
infected with WNV for 2 h in duplicate to test which
antibody could neutralize the anti-WNV activity. Infected
Vero cultures were observed for CPE daily, and culture
supernatants were collected at indicated times for WNV
viral RNA extraction and TaqMan RT-PCR [17].
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